DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
968
HCBE-11
1
Antibody
Investigational
Unknown
Unknown
Neoplasms
Tumor necrosis factor receptor superfamily member 3 agonist
HCBE-11
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TNX-100
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
TNX-100
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PERAKIZUMAB
1
Antibody
Investigational
Unknown
Unknown
Arthritis, Psoriatic
Interleukin 17A inhibitor
PERAKIZUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
867X5909JO
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RM-1929
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
RM-1929
×
Maximum Phase:
1
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VIBECOTAMAB
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
VIBECOTAMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
JD56EJA59S
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ORILANOLIMAB
1
Antibody
Investigational
Unknown
Unknown
Anemia, Hemolytic, Autoimmune
Unknown
ORILANOLIMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
1LTT6HMX9N
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RO6958688
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
RO6958688
×
Maximum Phase:
1
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MIK-BETA-1
1
Antibody
Investigational
Unknown
Unknown
Leukemia
Interleukin-2 receptor beta chain inhibitor
MIK-BETA-1
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PATRITUMAB DERUXTECAN
1
Antibody
Investigational
Unknown
Unknown
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung
DNA topoisomerase I inhibitor
PATRITUMAB DERUXTECAN
×
Maximum Phase:
1
First Approval:
None
UNII:
3XPI7EG4W8
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BMS-936564
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
BMS-936564
×
Maximum Phase:
1
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MLN-2704
1
Antibody
Investigational
Unknown
Unknown
Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Glutamate carboxypeptidase II binding agent
MLN-2704
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FP-1305
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
FP-1305
×
Maximum Phase:
1
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1D09C3
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
1D09C3
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
REGAVIRUMAB
1
Antibody
Investigational
Unknown
Unknown
Unknown
Envelope glycoprotein B inhibitor
REGAVIRUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ABAGOVOMAB
1
Antibody
Investigational
Unknown
Unknown
Fallopian Tube Neoplasms; Peritoneal Neoplasms; Ovarian Neoplasms
Mucin-16 other
ABAGOVOMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
3YK0326U7X
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
INDIUM IN 111 ALTUMOMAB PENTETATE
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
INDIUM IN 111 ALTUMOMAB PENTETATE
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CEVOSTAMAB
1
Antibody
Investigational
Unknown
Unknown
Multiple Myeloma
Unknown
CEVOSTAMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RG-1550
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
RG-1550
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BOS161721
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
BOS161721
×
Maximum Phase:
1
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
HEFI-1
1
Antibody
Investigational
Unknown
Unknown
Lymphoma; Neoplasms
Tumor necrosis factor receptor superfamily member 8 binding agent
HEFI-1
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
NACOLOMAB TAFENATOX
1
Antibody
Investigational
Unknown
Unknown
Unknown
Trophoblast glycoprotein cross-linking agent
NACOLOMAB TAFENATOX
×
Maximum Phase:
1
First Approval:
None
UNII:
PRC47TA1NU
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LETOLIZUMAB
1
Antibody
Investigational
Unknown
Unknown
Graft vs Host Disease
Unknown
LETOLIZUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
449MIE2SD6
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MILATUZUMAB
1
Antibody
Investigational
Unknown
Unknown
Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Multiple Myeloma; Plasmacytoma
HLA-DR antigens-associated invariant chain antagonist
MILATUZUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
2OP4E0GC6V
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CYT-500 177LU
1
Antibody
Investigational
Unknown
Unknown
Prostatic Neoplasms
Glutamate carboxypeptidase II binding agent
CYT-500 177LU
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VANTICTUMAB
1
Antibody
Investigational
Unknown
Unknown
Breast Neoplasms; Neoplasms; Pancreatic Neoplasms
Frizzled-1 antagonist
VANTICTUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
88WBI2D80S
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FLANVOTUMAB
1
Antibody
Investigational
Unknown
Unknown
Melanoma
5,6-dihydroxyindole-2-carboxylic acid oxidase other
FLANVOTUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
ZNV4738BS6
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
IDEC-159 111IN
1
Antibody
Investigational
Unknown
Unknown
Colorectal Neoplasms
Tumor-associated antigen 72 binding agent
IDEC-159 111IN
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MEDI-4212
1
Antibody
Investigational
Unknown
Unknown
Dermatitis, Atopic; Rhinitis, Allergic, Seasonal
Ig epsilon chain C region inhibitor
MEDI-4212
×
Maximum Phase:
1
First Approval:
None
UNII:
XK0D8BK5WY
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MANELIMAB
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
MANELIMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
U3OZ7HX207
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ELUVIXTAMAB
1
Antibody
Investigational
Unknown
Unknown
Leukemia, Myeloid, Acute; Myelodysplastic Syndromes
Unknown
ELUVIXTAMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
NIVATROTAMAB
1
Antibody
Investigational
Unknown
Unknown
Small Cell Lung Carcinoma
Unknown
NIVATROTAMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
A27.15
1
Antibody
Investigational
Unknown
Unknown
Leukemia; Multiple Myeloma; Myelodysplastic Syndromes; Myeloproliferative Disorders
Transferrin receptor protein 1 antagonist
A27.15
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TAVOLIMAB
1
Antibody
Investigational
Unknown
Unknown
Neoplasms
Unknown
TAVOLIMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
4LU9B48U4D
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LBY-135
1
Antibody
Investigational
Unknown
Unknown
Unknown
Tumor necrosis factor receptor superfamily member 10B agonist
LBY-135
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TELISOTUZUMAB
1
Antibody
Investigational
Unknown
Unknown
Neoplasms
Hepatocyte growth factor receptor inhibitor
TELISOTUZUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
R15ZW356HN
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1
2
…
7
8
9
10
11
12
13
…
27
28
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA